Pentoxifylline prevents spontaneous brain ischemia in stroke-prone rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 310, Issue 3, 2004, Pages 890-895

  Banfi, Cristina ^a,b   Sironi, Luigi ^a   De Simoni, Grazia ^c   Gelosa, Paolo ^a   Barcella, Simona ^a   Perego, Carlo ^c   Gianazza, Elisabetta ^a   Guerrini, Uliano ^a   Tremoli, Elena ^a,b   Mussoni, Luciana ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b CENTRO CARDIOLOGICO MONZINO   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PENTOXIFYLLINE; PROTEIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY FLUID; BRAIN ISCHEMIA; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; GLIA CELL; MACROPHAGE; MALE; NEUROPATHOLOGY; NEUROPHARMACOLOGY; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEINURIA; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; STROKE;

ANIMALS; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DISEASE MODELS, ANIMAL; INFLAMMATION; MALE; PENTOXIFYLLINE; PROTEINURIA; RATS; RATS, INBRED SHR; VASODILATOR AGENTS;

EID: 4243141761     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.067090     Document Type: Article

References (37)

1. Abumiya T, Masuda J, Kawai J, Suzuki T, and Ogata J (1996) Heterogeneity in the appearance and distribution of macrophage subsets and their possible involvement in hypertensive vascular lesions in rats. Lab Investig 75:125-136.
2. Bahra PS, Rainger GE, Wautier JL, and Nash GB (2001) Effects of pentoxifylline on the different steps during adhesion and transendothelial migration of flowing neutrophils. Cell Biochem Funct 19:249-257.
3. Bath PM, Bath FJ, and Asplund K (2000) Pentoxifylline, propentofylline and pentifylline for acute ischaemic stroke (Review). Cochrane Database Syst Rev 2:CD000162.
4. Bhat VB and Madyastha KM (2001) Antioxidant and radical scavenging properties of 8-oxo derivatives of xanthine drugs pentoxifylline and lisofylline. Biochem Biophys Res Commun 288:1212-1217.
5. Castillo J, Moro MA, Blanco M, Leira R, Serena J, Lizasoain I, and Davalos A (2003) The release of tumor necrosis factor-alpha is associated with ischemic tolerance in human stroke. Ann Neurol 54:811-819.
6. Creager MA (2001) Medical management of peripheral arterial disease. Cardiol Rev 9:238-245.
7. Dominguez-Jiménez C, Sancho D, Nieto M, Montoya MC, Barreiro O, Sanchez-Madrid F, and Gonzalez-Amaro R (2002) Effect of pentoxifylline on polarization and migration of human leukocytes. J Leukoc Biol 71:588-596.
8. Dong RP, Umezawa Y, Ikushima H, Munakata Y, Schlossman SF, and Morimoto C (1997) Different regulatory effects of pentoxifylline on human T cell activation pathways. J Clin Immunol 17:247-252.
9. Ducloux D, Bresson-Vautrin C, and Chalopin J (2001) Use of pentoxifylline in membranous nephropathy. Lancet 357:1672-1673.
10. Eun BL, Liu XH, and Barks JD (2000) Pentoxifylline attenuates hypoxic-ischemic brain injury in immature rats. Pedriatr Res 47:73-78.
11. Ginis I, Jaiswal R, Klimanis D, Liu J, Greenspon J, and Hallenbeck J (2002) TNF-α induced tolerance to ischemic injury involves differential control of NF-kB transactivation: the role of NF-kB association with p300 adaptor. J Cereb Blood Flow Metab 22:142-152.
12. Gonzalez-Amaro R, Portales-Perez D, Baranda L, Redondo JM, Martinez-Martinez S, Yanez-Mo M, Garcia-Vicuna R, Cabanas C, and Sanchez-Madrid F (1998) Pentoxifylline inhibits adhesion and activation of human T lymphocytes. J Immunol 161:65-72.
13. Guerrini U, Sironi L, Tremoli E, Cimino M, Pollo B, Calvio AM, Paoletti R, and Asdente M (2002) New insights into brain damage in stroke-prone rats. A nuclear magnetic imaging study. Stroke 33:825-830.
14. Haddad JJ, Land SC, Tarnow-Mordi WO, Zembala M, Kowalczyk D, and Lauterbach R (2002) Immunopharmacological potential of selective phosphodiesterase inhibition. I. Differential regulation of lipopolysaccharide- mediated proinflammatory cytokine (interleukin-6 and tumor necrosis factor-alpha) biosynthesis in alveolar epithelial cells. J Pharmacol Exp Ther 300:559-566.
15. Hallenbeck JM (2002) The many faces of tumor necrosis factor in stroke. Nat Med 8:1363-1368.
16. Hillegass LM, Griswold DE, Brickson B, and Albrightson-Winslow C (1990) Assessment of myeloperoxidase activity in whole rat kidney. J Pharmacol Methods 24:285-295.
17. Iwamoto H, Kozaki K, Nakamura N, Hama K, Narumi K, Matsuno N, Kuzuoka K, Taira S, Kihara Y, Uchiyama M, et al. (2002) Beneficial effects of pentoxifylline and propentofylline on the warm ischemic injury of rat livers. Transplant Proc 34:2677-2678.
18. Kim YK, Yoo JH, Woo JS, Jung JS, Kim BS, and Kim SY (2001) Effect of pentoxifylline on ischemic acute renal failure in rabbits. Ren Fail 23:757-772.
19. Kruuse C, Jacobsen TB, Thomsen LL, Hasselbalch SG, Frandsen EK, Dige-Petersen H, and Olesen J (2000) Effects of the non-selective phosphodiesterase inhibitor pentoxifylline on regional cerebral blood flow and large arteries in healthy subjects. Eur J Neurol 7:629-638.
20. Labs KH, Labs R, and Rossner M (1997) Clinical experience with pentoxifylline. Atherosclerosis 131:37-39.
21. Laurat E, Poirier B, Tupin E, Caligiuri G, Hansson GK, Bariety J, and Nicoletti A (2001) In vivo dowregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 104:197-202.
22. Lindsberg PJ and Grau AJ (2003) Inflammation and infections as risk factors for ischemic stroke. Stroke 34:2518-2532.
23. Marcinkiewicz J, Grabowska A, Lauterbach R, and Bobek M (2000) Differential effects of pentoxifylline, a non-specific phosphodiesterase inhibitor, on the production of IL-10, IL-12, p40 and p35 subunits by murine peritoneal macrophages. Immunopharmacology 49:335-343.
24. Neuner P, Klosner G, Pourmojib M, Knobler R, and Schwarz T (1997) Pentoxifylline in vivo and in vitro down-regulates the expression of the intercellular adhesion molecule-1 in monocytes. Immunology 90:435-439.
25. Samardzic T, Jankovic V, Stosic-Grujicic S, Popadic D, and Trajkovic V (2001) Pentoxifylline inhibits the synthesis and IFN-gamma-inducing activity of IL-18. Clin Exp Immunol 124:274-281.
26. Savas S, Delibas N, Savas C, Sutcu R, and Cindas A (2002) Pentoxifylline reduces biochemical markers of ischemia-reperfusion induced spinal cord injury in rabbits. Spinal Cord 40:224-229.
27. Seiffge D (1997) Pentoxifylline: its influence on interaction of blood cells with the vessel wall. Atherosclerosis 131:27-28.
28. Sener G, Akgun U, Satiroglu H, Topaloglu U, and Keyer-Uysal M (2001) The effect of pentoxifylline on intestinal ischemia/reperfusion injury. Fundam Clin Pharmacol 15:19-22.
29. Sirin BH, Yilik L, Coskun E, Ortac R, and Sirin H (1998) Pentoxifylline reduces injury of the brain in transient ischaemia. Acta Cardiol 53:89-95.
30. Sironi L, Calvio AM, Bellosta S, Lodetti B, Guerrini U, Monetti M, Tremoli E, and Mussoni L (2003) Endogenous proteolytic activity in a rat model of spontaneous cerebral stroke. Brain Res 974:184-192.
31. Sironi L, Tremoli E, Miller I, Guerrini U, Calvio AM, Eberini I, Gemeiner M, Asdente M, Paoletti R, and Gianazza E (2001) Acute-phase proteins before cerebral ischemia in stroke prone rats: identification by proteomics. Stroke 32: 753-760.
32. Tanito M, Nakamura H, Kwon YW, Teratani A, Masutani H, Shioji K, Kishimoto C, Ohira A, Horie R, and Yodoi J (2004) Enhanced oxidative stress and impaired thioredoxin expression in spontaneously hypertensive rats. Antioxid Redox Signal 6:89-97.
33. Teixeira MM, Gristwood RW, Cooper N, and Hellewell PG (1997) Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs for the future? Trends Pharmacol Sci 18:164-170.
34. Thabut G, Brugiere O, Leseche G, Stern JB, Fradj K, Herve P, Jebrak G, Marty J, Fournier M, and Mal H (2001) Preventive effect of inhalated nitric oxide and pentoxifylline on ischemia/reperfusion injury after lung transplantation. Transplantation 71:1295-1300.
35. Toung TJ, Kirsch JR, Maruki Y, and Traystman RJ (1994) Effects of pentoxifylline on cerebral blood flow, metabolism and evoked response after total cerebral ischemia in dogs. Crit Care Med 22:273-281.
36. Valenzuela A (1991) The biological significance of malondialdehyde determination in the assessment of tissue oxidative stress. Life Sci 48:301-309.
37. Windmeier C and Gressner AM (1997) Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis. Gen Pharmacol 29:181-196.